https://www.selleckchem.com/products/azd4573.html
tion in adults. This trial was registered at clinicaltrials.gov as NCT02585102. Stage III melanoma is a heterogenous disease, and the number of tumor-involved lymph nodes is the most significantly unfavorable prognostic indicator for relapse and outcome. The aim of this study is to investigate the possible effects of the various clinicopathological factors on the course of node-positive stage III disease. A total of 389 node-positive stage III cutaneous melanomas were included in the study and analyzed retrospectively. All underwent pat
Like
Comment
Share
